13.95

10.86% -1.70

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $13.95, with a volume of 3.35M. It is down -10.86% in the last 24 hours and up +127.57% over the past month. Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Previous Close:

$15.65

Open:

$15.57

24h Volume:

3.35M

Relative Volume:

1.83

Market Cap:

$721.18M

Revenue:

$170.44M

Net Income/Loss:

$-193.88M

P/E Ratio:

-3.7159

EPS:

-3.7541

Net Cash Flow:

$-126.38M

1W Performance:

+5.05%

1M Performance:

+127.57%

6M Performance:

-4.39%

1Y Performance:

+53.97%

1-Day Range:

$13.42

$15.65

1-Week Range:

$13.42

$15.88

52-Week Range:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

371

Twitter

@REGENXBIO

Next Earnings Date

2026-08-06

Latest SEC Filings

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGNX Regenxbio Inc	13.95	721.18M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Feb-11-25	Downgrade	Goldman	Buy → Neutral
Feb-07-25	Resumed	Raymond James	Outperform
Nov-15-24	Resumed	Morgan Stanley	Overweight
Oct-10-24	Resumed	Raymond James	Outperform
Jun-07-24	Initiated	Goldman	Buy
Mar-11-24	Initiated	H.C. Wainwright	Buy
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-21-24	Resumed	Raymond James	Outperform
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

Jul 10, 2026

RegenxBio doses first patient in phase 2b/3 trial for DR - Eyes On Eyecare

Jul 10, 2026

Jul 09, 2026